Surprisingly, some PI3K inhibitors are approved for the clinical treatment of human cancers, suggesting that the PI3K/Akt signaling pathway has an undeniable role and unlimited potential in tumor targeted therapy (YANG et al., 2019). Here, AKT1 is linked to neoplasm.